EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

Paolo Dapavo, Matteo Megna, Marina Talamonti

Dermatology Reports · 09.08.2024 · 17 (1)

DOI: 10.4081/dr.2024.9999 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology Reports, online erschienen am 09.08.2024. Verfasst von Paolo Dapavo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Section of Dermatology, University of Turin. paolo.dapavo@unito.it. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is an inflammatory chronic disease of the skin, typically located on the extensor surfaces of the body and the trunk. Patients with psoriasis can often present multiple characteristics, such as lesions located in difficult-to-treat (DTT) areas or high severity of the disease, which can negatively affect their quality of life. There is a lack of consensus in identifying the best therapy for these complex patient populations, especially after the failure of one or multiple lines of therapy. In this regard, we report a case series describing patients with psoriasis located in different DTT areas or presenting a high Psoriasis Area and Severity Index (PASI) score at baseline and treated ineffectively with prior lines of therapy. Finally, patients achieved complete remission following therapy with tildrakizumab 200 mg (anti-IL-23p19), highlighting its potential efficacy in these patient populations.

Autor:innen und Institutionen

  • Department of Medical Sciences, Section of Dermatology, University of Turin. paolo.dapavo@unito.it.
  • Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples. Mat24@libero.it.
  • Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome. marina.talamonti@uniroma2.it.

Zitieren

APA

Dapavo, P., Megna, M., & Talamonti, M. (2024). Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis. Dermatology Reports, 17(1). https://doi.org/10.4081/dr.2024.9999

Vancouver

Dapavo P, Megna M, Talamonti M. Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis. Dermatology Reports. 2024;17(1). doi:10.4081/dr.2024.9999

BibTeX
@article{Dapavo2024,
  author = {Dapavo, Paolo and Megna, Matteo and Talamonti, Marina},
  title = {Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis},
  journal = {Dermatology Reports},
  year = {2024},
  volume = {17},
  number = {1},
  doi = {10.4081/dr.2024.9999}
}
Kostenlos starten →